STOCK TITAN

Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call on July 30, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and provide a corporate update. Investors can join the call by dialing (855) 728-4793 for domestic calls or (503) 343-6666 for international calls, using conference ID 2769677. A webcast will also be available on their website and archived for 30 days afterward.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., July 23, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, July 30, 2020 to report its second quarter 2020 financial results and provide a corporate update.

To access the live conference call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international), and refer to conference ID 2769677. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have one FDA-approved precision therapy and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. For more information, visit -1%26h%3D2220028578%26u%3Dhttp%253A%252F%252Fwww.blueprintmedicines.com%252F%26a%3Dwww.BlueprintMedicines.com&a=www.BlueprintMedicines.com" rel="nofollow">www.BlueprintMedicines.com and follow us on -1%26h%3D3232712528%26u%3Dhttps%253A%252F%252Ftwitter.com%252Fblueprintmeds%26a%3DTwitter&a=Twitter" rel="nofollow">Twitter (@BlueprintMeds) and -1%26h%3D277339298%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fblueprint-medicines%252F%26a%3DLinkedIn&a=LinkedIn" rel="nofollow">LinkedIn.

 

"Cision" View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-second-quarter-2020-financial-results-on-thursday-july-30-2020-301098587.html

SOURCE Blueprint Medicines Corporation

FAQ

When will Blueprint Medicines report its second quarter 2020 financial results?

Blueprint Medicines will report its second quarter 2020 financial results on July 30, 2020.

How can I access the Blueprint Medicines conference call?

You can access the conference call by dialing (855) 728-4793 domestically or (503) 343-6666 internationally, using conference ID 2769677.

Will there be a webcast of the Blueprint Medicines conference call?

Yes, a webcast of the conference call will be available on the Blueprint Medicines website under 'Events and Presentations'.

How long will the archived webcast of the conference call be available?

The archived webcast will be available for 30 days after the call.

Blueprint Medicines Corporation

NASDAQ:BPMC

BPMC Rankings

BPMC Latest News

BPMC Stock Data

5.67B
62.85M
0.9%
104.77%
6.16%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE